Posted by Michael Wonder on 01 Mar 2025
AbbVie receives positive CHMP opinion for upadacitinib (Rinvoq) for the treatment of adults with giant cell arteritis
28 February 2025 - The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis.
AbbVie today announced that the EMA's CHMP has adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg once daily) for the treatment of adult patients with giant cell arteritis.
